1. Home
  2. CCC vs BEAM Comparison

CCC vs BEAM Comparison

Compare CCC & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CCC Intelligent Solutions Holdings Inc.

CCC

CCC Intelligent Solutions Holdings Inc.

HOLD

Current Price

$6.64

Market Cap

3.1B

Sector

Technology

ML Signal

HOLD

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

HOLD

Current Price

$23.12

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CCC
BEAM
Founded
1980
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.1B
2.6B
IPO Year
2020
2019

Fundamental Metrics

Financial Performance
Metric
CCC
BEAM
Price
$6.64
$23.12
Analyst Decision
Buy
Buy
Analyst Count
8
12
Target Price
$8.94
$50.75
AVG Volume (30 Days)
9.2M
1.8M
Earning Date
04-30-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
82.31
EPS
0.06
N/A
Revenue
$1,057,001,000.00
$24,000.00
Revenue This Year
$10.22
N/A
Revenue Next Year
$8.58
$33.77
P/E Ratio
$114.83
N/A
Revenue Growth
11.88
33.33
52 Week Low
$4.08
$20.23
52 Week High
$8.68
$38.26

Technical Indicators

Market Signals
Indicator
CCC
BEAM
Relative Strength Index (RSI) 46.98 34.38
Support Level $6.63 $23.80
Resistance Level $7.79 $28.96
Average True Range (ATR) 0.32 1.43
MACD -0.13 -0.61
Stochastic Oscillator 32.34 2.26

Price Performance

Historical Comparison
CCC
BEAM

About CCC CCC Intelligent Solutions Holdings Inc.

CCC Intelligent Solutions Holdings Inc is a provider of cloud, mobile, AI, telematics, hyperscale technologies, and applications for the property and casualty insurance economy. The company's SaaS platform connects trading partners, facilitates commerce, and supports mission-critical, AI-enabled digital workflows. It operates in a single segment being Domestic segment, which provides SAAS platform for the P&C insurance economy and derives revenues from providing customers with software subscriptions to the platform in addition to providing professional services and non-software services. The company has its presence in the United States and China. The majority of the revenue is generated from the United States.

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.

Share on Social Networks: